Patient population for bioequivalence study [Regulatives / Guidelines]

posted by pash413 – India, 2017-10-06 17:33 (2724 d 13:32 ago) – Posting: # 17867
Views: 3,748

Dear David
Thanks for the reply.
We are talking about the generic drug with PK endpoint study submission.

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,670 registered users;
23 visitors (0 registered, 23 guests [including 9 identified bots]).
Forum time: 06:05 CET (Europe/Vienna)

An expert is one who knows more and more
about less and less.    Nicholas Murray Butler

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5